Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2 Investigators recommend further development of inhaled APN01, which…

Vienna, Austria, 18 October 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that two abstracts on its clinical stage lead program, APN401,…

Vienna, Austria, 11 October 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces its participation at three upcoming industry and investor conferences: BIO-Europe, Inv€$tival...

Although cancer represents a huge challenge for our healthcare systems, new immunotherapies and other advanced novel treatments mean hope is on the horizon. Cancer is one of the all-pervading topics...

1. Do cell therapies represent a breakthrough in cancer treatment? Mario Kuttke: It is really amazing how adoptive cell therapy (ACT), a form of cancer immunotherapy, has evolved so rapidly...

invIOs’s novel clinical stage lead therapeutic candidate, APN401, combines advances in immune cell therapy and RNA interference methods to treat advanced solid cancers. Immune therapy – hitting new targets Immune...

geared towards enabling innovation and growth invIOs becomes fully separate entity focused on advancing its unique EPiC cell therapy platform and clinical-stage immuno-oncology pipeline Vienna, Austria, 26 April 2022. APEIRON...

1. Ribonucleic acids have for a long time been DNA’s “little sister”. What’s so different between RNA and DNA? Alexander Dohnal: RNA and DNA have a lot in common. Chemical...